On Tuesday, Merck & Co Inc MRK reported fourth-quarter gross sales of $15.62 billion, up 7% 12 months over 12 months and barely beating the consensus estimate of $15.49 billion. Excluding the influence of overseas change, gross sales elevated 9%.
Merck reported adjusted EPS of $1.72, up from $0.03 a 12 months in the past and beating the consensus of $1.62. Decrease prices for enterprise improvement transactions and operational energy primarily drove the rise.
Merck expects fiscal 12 months 2025 gross sales of $64.1 billion-$65.6 billion versus a consensus of $67.31 billion.
Additionally Learn: RJK Jr.’s Involvement In Merck Lawsuit Faces Scrutiny Forward Of Senate Listening to
The gross sales vary displays a call to briefly pause Gardasil/Gardasil 9 shipments into China starting February 2025 by means of no less than mid-year.
Goldman Sachs analyst writes that Merck delivered robust operational efficiency throughout the vast majority of the corporate’s market-leading (Oncology), attractively rising (PAH), and re-emerging aggressive (Infectious illness) portfolios; nevertheless, weaker steerage was a supply of disappointment.
Analyst Chris Shibutani writes that the magnitude of the draw back transfer was overdone and maintains the Purchase ranking with a worth forecast of $135, up from a previous $129.
Throughout the industrial portfolio, the analyst stays bullish on Winrevair’s potential.
Analyst Shibutani writes that the corporate is well-equipped to put money into enterprise progress and prioritize capital allocation successfully. Their observe file exhibits that they will efficiently make strategic strikes—each aggressive, like buying Acceleron and Prometheus, and cautious, like passing on Seagen resulting from valuation issues.
BofA Securities writes Merck inventory’s valuation was too low for an above-average progress profile.
A BofA analyst notes that Merck has one of many strongest late-stage drug pipelines amongst its friends and stays a top-tier R&D firm. They nonetheless see extra potential positive factors than dangers at present ranges and preserve a Purchase ranking. Nevertheless, BofA writes the inventory might take a while to stabilize within the quick time period.
The analyst lowered the value goal from $118 to $112.
Worth Motion: MRK inventory is down 0.79% at $90.02 on the final test on Wednesday.
Learn Subsequent:
Picture through Merck
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
